Comparison of the Effectiveness of Magnesium Oxide and Vitamin C Supplementation in Prevention of Migraine Headaches

prevention

Clinical trial without control group, with parallel groups, single-blind, randomized, 82 patients

Location: Hazrat Rasoul Clinic, Shahrekord University of Medical Sciences, Method: 82 patients who met the inclusion criteria and did not meet the exclusion criteria were admitted to the study with consent and were randomly divided into two groups. One group received 250 mg of vitamin C daily for 2 months and the other group received magnesium oxide. The MSQ and Beck Depression Inventory are filled out by patients at the beginning and end of two months. Patients in both groups do not know which medication they are taking.

Inclusion criteria: 1. Their age is between 18 and 60 years. 2. According to ICHD-3 International Community Headache criteria, the diagnosis of migraine should be made by a neurologist at least one year in advance. 3. Diagnosis of moderate to severe migraine Exclusion criteria 1. Fever or evidence of infection 2. Simultaneous infection with other headaches 3. A history of major depression 4. Daily use of painkillers 5. Pregnancy or pregnancy intention 6. Having chronic diseases

Group one: 250 mg magnesium oxide tablets once daily orally for 8 weeks Group 2: Vitamin C supplement tablets of 250 mg once daily orally for 8 weeks

The effect of migraine headaches on daily activities based on the MSQ questionnaire Depression score based on Beck Depression Inventory

Regarding the method of blinding the study, after consulting again with the statistical consultant of the project to improve the scientific level of the study, it was decided that the type of randomization method in this two-way trial is blind so that the researcher and patients decide which drug is among the two drugs introduced in The schemes used are uninformed but the clinical caregiver divides and distributes the drugs in similar packages..

Randomization by random number table method: After filling the informed consent of the study participants, patients will be divided into two groups by random number table method and will receive and consume one of the two drugs studied in the plan.

Double blind blindness: The clinical researcher and the patients participating in the project are not aware of the type of drug used and only the clinical caregiver, knowing the type of drug, distributes it in similar envelopes. It should be noted that the drugs are similar in dose, color and shape. Also, the envelopes are nameless and recognizable only to the clinical caregiver.